Association between polycystic ovary syndrome and female-to-male transsexuality
|
|
- Oswald Grant
- 6 years ago
- Views:
Transcription
1 Human Reproduction Vol.22, No.4 pp , 2007 Advance Access publication December 13, 2006 doi: /humrep/del474 Association between polycystic ovary syndrome and female-to-male transsexuality Tsuyoshi Baba 1,5, Toshiaki Endo 1, Hiroyuki Honnma 1, Yoshimitsu Kitajima 1, Takuhiro Hayashi 1, Hiroshi Ikeda 2, Naoya Masumori 3, Hirofumi Kamiya 4, Osamu Moriwaka 4 and Tsuyoshi Saito 1 1 Department of Obstetrics and Gynecology, 2 Department of Psychiatry, 3 Department of Urology, Sapporo Medical University, Sapporo, Hokkaido, Japan and 4 Kamiya Ladies Clinic, Sapporo, Hokkaido, Japan 5 To whom correspondence should be addressed at: Department of Obstetrics and Gynecology, Sapporo Medical University, South 1 West 16, Chu-o-ku, Sapporo, Hokkaido , Japan. tbaba@sapmed.ac.jp BACKGROUND: The aim of this study is to understand the relationship between polycystic ovary syndrome (PCOS), altered hormonal characteristics and insulin resistance in female-to-male (FTM) transsexual patients. METHODS: We studied 69 Japanese FTM cases, aged years, who were seen in the Gender Identity Disorder Clinic of Sapporo Medical University Hospital between December 2003 and May The subjects had never received hormonal treatment or sex re-assignment surgery. Prior to treatment, they received physical examinations entailing measurement of anthropometric, metabolic and endocrine parameters, after which we compared the values obtained according to the presence or absence of PCOS and/or obesity. Insulin resistance was determined using the homeostasis model assessment of insulin resistance (HOMA-IR). RESULTS: Of the 69 participating FTM cases, 40 (58.0%) were found to have PCOS. Of the 49 for whom HOMA-IR was calculated, 15 (30.6%) also showed insulin resistance, whereas of the 59 for whom adiponectin was measured, 18 (30.5%) showed hypoadiponectinaemia. Of 69 for whom androgens were measured, 29 (39.1%) showed hyperandrogenaemia. Insulin resistance was associated with obesity but not with PCOS. In contrast, hyperandrogenaemia was associated with both PCOS and obesity. CONCLUSIONS: FTM transsexual patients have a high prevalence of PCOS and hyperandrogenaemia. Key words: Adiponectin/female-to-male transsexuality/hyperandrogenaemia/insulin resistance/polycystic ovary syndrome Introduction Gender identity disorder (GID) is a disagreement between biological sexual differentiation and self-declared gender identity. It is characterized by (i) a strong and persistent cross-gender identification and (ii) persistent discomfort with the biological sexual or gender role behaviours associated with one s sex. The aetiology of GID remains unclear, although endocrinological, neuroanatomical and psychosocial factors are all thought to be causally involved. For example, Collaer and Hines (1995) showed that gonadal hormones affect sexual differentiation. In addition, examination of females with congenital adrenal hyperplasia due to 21-hydroxylase deficiency, which results in excessive prenatal androgen exposure, revealed that early androgen exposure has a modest effect on gender identification (Berenbaum and Bailey, 2003). We established a GID clinic in 2003, and since then, more than 90 female-to-male (FTM) transsexuals have been seen there. Prior to treatment, most of these individuals exhibited polycystic ovarian morphology on ultrasonography as well as symptoms of hyperandrogenism (e.g. hyperandrogenaemia and hirsutism). Polycystic ovary syndrome (PCOS) is characterized by chronic anovulation, polycystic ovarian morphology, and biochemical and/or biological signs of hyperandrogenism (The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group, 2004). Most women with PCOS also exhibit insulin resistance and hyperinsulinaemia, which is independent of obesity (Dunaif et al., 1989). Insulin resistance is defined as a diminished ability of cells to respond to the action of insulin and predisposes one to type 2 diabetes mellitus. In addition, insulin resistance is associated with hypertension, dyslipidaemia, obesity and atherosclerotic cardiovascular disease (DeFronzo and Ferrannini, 1991). Numerous hormones and cytokines are known to regulate insulin action. Adipocytokines, such as adiponectin, leptin, resistin and tumour necrosis factor-a, are all involved in mediating insulin resistance. Among them, adiponectin is a circulating protein secreted by small adipocytes (Maeda et al., 1996). Notably, serum adiponectin levels are lower in patients with type 2 diabetes, obesity and coronary heart disease than in healthy subjects, and a number of studies have suggested that # The Author Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org 1011
2 T.Baba et al. adiponectin exerts an insulin sensitizing effect (Hotta et al., 2000; Weyer et al., 2001; Matsubara et al., 2002; Stefan and Stumvoll, 2002). Despite reports of an association between PCOS and adiponectin (Sieminska et al., 2004; Ardawi and Rouzi, 2005; Carmina et al., 2005), there have been no studies examining adiponectin levels in, or the prevalence of PCOS and insulin resistance, among FTM transsexuals. The aim of the present study, therefore, is to investigate the possible association between PCOS, insulin resistance and FTM transsexuality. Materials and methods Subjects The study population consisted of 69 Japanese FTM transsexual patients, years of age, who were seen in the GID clinic of Sapporo Medical University Hospital between December 2003 and May None of these women had ever received hormone treatment or sex re-assignment surgery. Psychological diagnoses were made by a specialized psychiatrist at the clinic according to the guidelines of our institution, the Japanese Society of Psychiatry and Neurology, ICD-10 and DSM-IV (World Health Organization, 1992; American Psychiatric Association, 1994). Patients who were found to have other psychiatric abnormalities such as schizophrenia or virilizing endocrine disorders were excluded. All patients were chromosomal and phenotypic females. Physical and biological study Prior to treatment, the patients received a physical examination. Transvaginal or transrectal ultrasonographic scans were performed using a 5 MHz probe, and serum endocrine analysis was performed during the follicular phase of their menstrual cycle. The measured hormones included luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol, prolactin, total testosterone, free testosterone, androstenedione and dehydroepiandrosterone sulphate (DHEAS). Elevated serum androgen concentrations were defined as: total testosterone 0.7 ng ml 21, free testosterone 1.0 pg ml 21, androstenedione 3.5 ng ml 21 and DHEAS 3500 pg ml 21. Adiponectin, fasting plasma glucose and fasting insulin levels were also measured, and insulin resistance was determined using the homeostasis model assessment of insulin resistance (HOMA-IR) (Matthews et al., 1985). HOMA-IR was calculated using the formula: FPG (mg dl 21 )- IRI (mu ml 21 )/405, where FPG is the fasting plasma glucose level and IRI is the fasting insulin level. Patients with an HOMA-IR. 2.0 were considered to be insulin resistant. Adiponectin levels,8.0 mgml 21 were considered abnormal. PCOS criteria The diagnosis of PCOS was based on the Rotterdam 2003 criteria, which include oligo- and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovarian morphology. Women who met at least two of the above-mentioned criteria were diagnosed as having PCOS. Results On the basis of the Rotterdam 2003 criteria, 40 of the 69 FTM transsexual patients (58.0%) participating in this study were diagnosed as having PCOS. Of those, 11 were obese (BMI 25 kg m 22 ) and 29 were lean (BMI,25 kg m 22 ). Among the 29 patients without PCOS, only five were obese. Tables I and II summarize the anthropometric, endocrine and metabolic characteristics of the study population. There were statistically significant differences between the PCOS and non-pcos groups with respect to LH (P, 0.001) and androstenedione (P, 0.05) levels. Although the difference was not statistically significant, the PCOS group also had slightly higher total testosterone levels than the non-pcos group ( versus , P ¼ ). When compared with the lean group, the obese group had significantly higher fasting insulin (P, 0.05), higher HOMA-IR (P, 0.05), lower adiponectin (P ¼ ) and higher total testosterone (P, 0.05) (Table I). Patients in the obese PCOS group had significantly higher LH (P, 0.05), higher FSH (P, 0.05) and higher androstenedione (P, 0.005) than those in the obese non-pcos group. Although the differences were not statistically significant, possibly due to the lack of power, the obese PCOS group also had higher total testosterone Table I. The characteristics of study subjects Polycystic ovary syndrome (PCOS) (n ¼ 40) Non-PCOS (n ¼ 29) Obese (n ¼ 16) Lean (n ¼ 53) Age BMI * LH ** FSH Estradiol Prolactin Fasting plasma glucose Fasting insulin *** Homeostasis model assessment of insulin resistance *** Adiponectin **** Total testosterone *** Androstenedione ***** Dehydro epiandrosterone sulphate Data are expressed as mean + SD. Statistical analyses were performed using the Mann Whitney U-test. *P, versus lean group, **P, versus non-pcos group, ***P, 0.05, ****P ¼ , *****P,
3 PCOS and female-to-male transsexuality Table II. The characteristics of obese and lean subjects Obese polycystic ovary syndrome (PCOS) (n ¼ 11) Obese non-pcos (n ¼ 5) Lean PCOS (n ¼ 29) Lean non-pcos (n ¼ 24) Age BMI LH * ** FSH * Estradiol Prolactin Fasting plasma glucose Fasting insulin Homeostasis model assessment of insulin resistance Adiponectin Total testosterone Androstenedione *** Dehydro epiandrosterone sulphate Data are expressed as mean + SD. Statistical analyses were performed using the Mann Whitney U-test. *P, 0.05, **P, versus lean non-pcos group, ***P, versus obese non-pcos group. ( versus , P ¼ ) and DHEAS ( versus , P ¼0.1125) levels than the obese non-pcos group. There were no statistically significant differences between the lean PCOS group and the lean non-pcos group, except with respect to LH (P, ) (Table II). Of the 49 patients for whom HOMA-IRs were calculated, 15 (30.6%) showed insulin resistance. These insulin resistant cases were 10 out of 32 (31.3%) patients in the PCOS group and 5 out of 17 (29.4%) patients in the non-pcos group. Within the various groups, the percentages of patients exhibiting abnormal HOMA-IR were 72.7% (obese), 17.1% (lean), 62.5% (obese PCOS), 100% (obese non-pcos), 19.0% (lean PCOS) and 14.3% (lean non-pcos). A statistically significant difference was seen only between the obese and lean groups (P, 0.005, OR ¼ 12.89, 95% CI: ) (Figure 1). Of the 59 patients in whom serum adiponectin levels were measured, 18 (30.5%) showed hypoadiponectinaemia. Within the groups, the percentages of patients exhibiting hypoadiponectinaemia were 33.3% (PCOS), 26.9% (non-pcos), 71.4% (obese), 17.8% (lean), 77.8% (obese PCOS), 60.0% (obese non-pcos), 16.7% (lean PCOS) and 19.0% (lean non-pcos). A statistically significant difference was seen only between the obese and lean groups (P, , OR ¼ 11.56, 95% CI: ) (Figure 2). Elevated levels of at least one of the four measured androgens (hyperandrogenaemia) were seen in 27 of the 69 study subjects (39.1%). Within the groups, the percentages of patients exhibiting hyperandrogenaemia were 57.5% (PCOS) 13.8% (non-pcos), 62.5% (obese), 32.1% (lean), 81.8% (obese PCOS), 20.0% (obese non-pcos), 48.3% (lean PCOS), and 12.5% (lean non-pcos) (Figures 3 and 4). In most cases, high levels of androstenedione and DHEA coexisted with high testosterone levels. There were statistically significant differences between the PCOS and non-pcos groups (P, , OR ¼ 8.46, 95% CI: ), the obese and lean groups (P, 0.05, OR ¼ 3.53, 95% CI: ), the obese PCOS and obese non-pcos groups (P, 0.05, OR ¼ 18.00, 95% CI: ) and the lean PCOS and lean non-pcos groups (P, 0.01, OR ¼ 6.53, 95% CI: ). There were no statistically significant differences between the obese PCOS and lean PCOS (P ¼ ) groups or between the obese non-pcos and lean non-pcos groups (P ¼ ). Figure 1. Percentage of women with insulin resistance based on homeostasis model assessment of insulin resistance (HOMA-IR). HOMA-IR 2.0 was considered insulin resistant. 1013
4 T.Baba et al. Figure 2. Percentage of women with hypoadiponectinaemia. Adiponectin levels,8.0 mgml 21 were considered abnormal. Discussion PCOS is a common hormonal disorder that, according to previously published diagnostic criteria (Futterweit, 1999; Ehrmann, 2005), affects 5 10% of women of reproductive age. In contrast, our study shows that as many as 58% of FTM transsexual patients exhibit PCOS prior to treatment. Using the Rotterdam criteria, patients with ovulatory menstrual cycles, polycystic ovaries and hyperandrogenaemia, and who had been excluded from the PCOS group on the basis of the earlier diagnostic criteria, were also diagnosed as having PCOS. Consequently, the prevalence of PCOS was estimated to be higher than previously thought. Unfortunately, there are no data available on the prevalence of PCOS diagnosed based on the Rotterdam criteria among healthy Japanese women. A population-based study may be needed to compare the prevalence of PCOS among FTM transsexual individuals and among women in the general population. Notably, PCOS often accompanies hyperandrogenism, insulin resistance and obesity, which suggests that FTM transsexual patients are likely to show excessive androgen levels. In adult humans, hypersecretion of androgens causes the ovary to have a polycystic appearance; moreover, it is known that ovaries removed from FTM transsexual patients after long-term androgen therapy are histopathologically polycystic. These findings thus suggest that FTM transsexualism is frequently associated with PCOS (Futterweit and Deligdisch, 1986; Pache et al., 1993). The aetiology of transsexualism remains unclear, although high androgen levels during critical periods of brain differentiation have been shown to cause male-like behaviour in female animals. In human studies, genetic females with congenital adrenal hyperplasia are more likely to show genderatypical play behaviour and gynephilic sexual orientation (Meyer-Bahlburg, 1979; Dittmann et al., 1992). In that regard, the prevalence of PCOS is significantly higher among lesbian women than among heterosexual women, and lesbian women with PCOS have more pronounced hyperandrogenism than heterosexual women with PCOS (Agrawal et al., 2004). In an earlier study, males with a 5a-reductase deficiency showed diminished in utero production of dihydrotestosterone (Imperato-McGinley et al., 1979), which resulted in ambiguous genitalia in the affected male fetus. Indeed, affected infants were often considered to be girls at birth and raised as females. Virilization occurred during puberty, however, Figure 3. Percentage of women with hyperandrogenaemia. Elevated serum androgen levels were defined as follows: total testosterone, 0.7 ng ml 21 ; free testosterone, 1.0 pg ml 21 ; androstenedione, 3.5 ng ml 21 and dehydroepiandrosterone sulphate 3500 pg ml
5 PCOS and female-to-male transsexuality Figure 4. Percentage of women with hyperandrogenaemia. Elevated serum androgen levels were defined as follows: total testosterone, 0.7 ng ml 21 ; free testosterone, 1.0 pg ml 21 ; androstenedione, 3.5 ng ml 21 and dehydroepiandrosterone sulphate 3500 pg ml 21. because testicular biosynthesis of testosterone and its peripheral actions were normal. These children typically began to realize that they were different from other girls when they were between 7 and 12 years of age, with 17 of the 18 children studied changing their gender identity to male. Thus, androgen production during the pubertal period appears to make a strong contribution to formation of male gender identity. This idea was further confirmed in another study of complete androgen insensitivity syndrome, which results from androgen receptor dysfunction and is a useful model for studying the effects of androgens during psychosexual development. Patients with this disorder are 46, XY individuals with testes, normal or high levels of testosterone and normal female external genitalia. Wisniewski et al. (2000) reported that all 14 of the cases of complete androgen insensitivity syndrome they studied reported satisfaction with being a woman. Taken together, these studies indicate that androgen production during both the fetal and prepubertal periods is closely related to the formation of gender identity, although other factors may also contribute. Obesity is also a characteristic of at least 50 65% of women with PCOS (Futterweit, 1999). In our study, however, only 11 of 40 (27.5%) FTM cases with PCOS were obese and, overall, only 16 of 69 (23.2%) were obese. Obesity reduces the levels of circulating adiponectin, which is related to insulin resistance. It also worsens insulin resistance through dysregulated production of other cytokines and proteins, including tumour necrosis factor-a, leptin and resistin. In the present study, the obese FTM group showed significantly higher incidence of high HOMA-IR and/or low adiponectin than the lean group. In contrast, there was little association between the occurrence of PCOS and high HOMA-IR or hypoadiponectinaemia. Thus, insulin resistance in FTM transsexual patients was associated with obesity, not with PCOS, itself. Administration of exogenous androgen, the treatment of choice for FTM transsexual patients, causes insulin resistance. Given that insulin resistance is closely related to type 2 diabetes, hypertension, dyslipidacmia and cardiovascular disease, complications associated with PCOS would be expected to represent a significant health risk for FTM transsexual cases. Hyperandrogenism is a common finding in PCOS and FTM transsexual patients (Bosinski et al., 1997). Notably, 39.1% of untreated FTM transsexual patients showed high levels of at least one androgen. In our experience, plasma androgen levels in PCOS patients without transsexualism do not exceed the following concentrations: total testosterone, 2.0 ng ml 21 ; free testosterone, 2.0 pg ml 21 ; androstenedione, 5.0 ng ml 21 and DHEAS, 5000 pg ml 21. It should be noted, however, that we experienced five cases of FTM transsexuality with extremely high androgen levels. In one case of extremely high testosterone levels, the total and free testosterone concentrations were 4.3 ng ml 21 and 4.32 pg ml 21, respectively. Among the other cases, one individual showed an androstenedione level of 5.3 ng ml 21 and another showed a DHEAS level of 5560 pg ml 21. All these cases were complicated by PCOS. The very high levels make one suspect that these individuals have been self-administering exogenous androgen, as self-medication by transsexual patients is frequently seen in Japan. For instance, in a study carried out at the Okayama University, Okayama, Japan, 127 of 312 (40.7%) FTM patients self-medicated. In our experience, however, almost all FTM patients taking exogenous androgen show haemoconcentration (haematocrit.45%), and the haematocrit levels of our five patients were,45%. Moreover, androgen therapy quickly induces amenorrhoea, irrespective of the state of the patient s menstrual cycle before treatment, and our patients were all cycling at the time of their first clinic visit. Finally, self-medication was favourable to their treatment, so it was not in their interest to deceive us. It thus seems highly unlikely to us that it is by chance that most cases of FTM transsexuality are complicated by PCOS and extremely high androgen levels. Among the subjects in the present study, those who exhibited PCOS were more likely to show hyperandrogenaemia than those who did not. In addition, patients in the obese group were more likely to show hyperandrogenaemia than those in 1015
6 T.Baba et al. the lean group. Given that PCOS and obesity are thought to be associated, we compared the obese PCOS group with obese non-pcos group and lean PCOS group with lean non-pcos group to eliminate the influence of the BMI. The results of these comparisons suggested that PCOS is associated with hyperandrogenaemia. Similarly, we compared the obese PCOS group with lean PCOS group and obese non-pcos group with lean non-pcos group to eliminate the influence of the PCOS. These findings showed that there is little relationship between obesity itself and hyperandrogenaemia. Our findings show that many cases of FTM transsexuality are associated with PCOS and hyperandrogenaemia, which suggests that they are important factors in the pathogenesis of FTM transsexualism. In addition, our findings also suggest that when administering androgen therapy to FTM transsexual patients, it is important that practitioners keep in mind that this treatment worsens insulin resistance. Acknowledgements This study was supported by a grant-in aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan. We thank Dr Kengo Manase for his help. References Agrawal R, Sharma S, Bekir J, Conway G, Bailey J, Balen AH and Prelevic G. (2004) Prevalence of polycystic ovaries and polycystic ovary syndrome in lesbian women compared with heterosexual women. Fertil Steril 82, American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). American Psychiatric Press, Washington, DC, USA. Ardawi MS and Rouzi AA (2005) Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril 83, Berenbaum SA and Bailey JM (2003) Effects on gender identity of prenatal androgens and genital appearance: evidence from girls with congenital adrenal hyperplasia. J Clin Endocrinol Metab 88, Bosinski HAG, Peter M, Bonatz G, Arndt R, Heidenreich M, Sippell WG and Wille R (1997) A higher rate of hyperandrogenic disorders in female-to-male transsexuals. Psychoneuroendocrinology 22, Carmina E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM, Lombardi G and Lobo RA (2005) Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol 152, Collaer ML and Hines M (1995) Human behavioral sex differences: a role for gonadal hormones during early development? Psychol Bull 118, DeFronzo RA and Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM obesity hypertension dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14, Dittmann RW, Kappes ME and Kappes MH (1992) Sexual behavior in adolescent and adult females with congenital adrenal hyperplasia. Psychoneuroendocrinology 17, Dunaif A, Segal KR, Futterweit W and Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38, Ehrmann DA (2005) Polycystic ovary syndrome. N Engl J Med 352, Futterweit W (1999) Polycystic ovary syndrome: clinical perspectives and management. Obstet Gynecol Surv 54, Futterweit W and Deligdisch L (1986) Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. J Clin Endocrinol Metab 62, Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N and Maeda K et al. (2000) Plasma concentration of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20, Imperato-McGinley J, Peterson RE, Gautier T and Sturla E (1979) Androgens and the evolution of male-gender identity among male pseudohermaphrodites with 5a-reductase deficiency. N Engl J Med 300, Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y and Matsubara K (1996) cdna cloning and expression of a novel adipose specific collagen-like factor, apm1. Biochem Biophys Res Commun 221, Matsubara M, Maruoka S and Katayose S (2002) Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 87, Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC (1985) Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, Meyer-Bahlburg HFL (1979) Sex hormones and female homosexuality: a critical examination. Arch Sex Behav 8, Pache TD, de Jong FH, Hop WC and Fauser BC (1993) Association between ovarian changes assessed by transvaginal sonography and clinical and endocrine signs of the polycystic ovary syndrome. Fertil Steril 59, Sieminska L, Marek B, Kos-Kudla B, Niedziolka D, Kajdaniuk D, Nowak M and Glogowska-Szelag J (2004) Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters. J Endocrinol Invest 27, Stefan N and Stumvoll M (2002) Adiponectin its role in metabolism and beyond. Horm Metab Res 34, The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19, Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE and Tataranni PA (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86, Wisniewski AB, Migeon CJ, Meyer-Bahlburg HFL, Gearhart JP, Berkovitz GD, Brown TR and Money J (2000) Complete androgen insensitivity syndrome: long-term medical, surgical, and psychosexual outcome. J Clin Endcrinol Metab 85, World Health Organization (1992) The ICD-10 classification of mental and behavioral disorders. Clinical descriptions and diagnostic guidelines. World Health Organization, Geneva, Switzerland. Submitted on August 15, 2006; resubmitted on October 10, 2006; accepted on October 23,
METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY
Vuk Vrhovac University Clinic Dugi dol 4a, HR-10000 Zagreb, Croatia Original Research Article Received: February 18, 2010 Accepted: March 3, 2010 METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN
More informationDetermining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)
Abstract: Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs) Ashraf Olabi, Ghena Alqotini College of medicine, Aleppo University Hospital Obstetrics and Gynacology, Syria.
More informationClinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
POLYCYSTIC OVARY SYNDROME Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes Ettore Guastella, M.D., a Rosa Alba Longo, M.D., b and Enrico Carmina, M.D. b a Department
More informationArticle PCOS in lesbian and heterosexual women treated with artificial donor insemination
RBMOnline - Vol 17. No 3. 2008 398-402 Reproductive BioMedicine Online; www.rbmonline.com/article/3252 on web 22 July 2008 Article PCOS in lesbian and heterosexual women treated with artificial donor insemination
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationASSOCIATION OF INSULIN RESISTANCE AND SERUM 25 OH VITAMIN-D IN INDIAN WOMEN WITH POLYCYSTIC OVARY SYNDROME
RESEARCH ARTICLE ASSOCIATION OF INSULIN RESISTANCE AND SERUM 25 OH VITAMIN-D IN INDIAN WOMEN WITH POLYCYSTIC OVARY SYNDROME Amar Nagesh Kumar 1, Jupalle Nagaiah Naidu 2, Uppala Satyanarayana 3, Medabalmi
More informationPrevalence of polycystic ovarian syndrome in the Buraimi region of Oman
Original Article Brunei Int Med J. 2012; 8 (5): 248-252 Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman Usha VARGHESE 1 and Shaji VARUGHESE 2, 1 Department of Internal Medicine
More informationX/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.
0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2005-1457 EXTENSIVE CLINICAL EXPERIENCE Relative
More informationEndocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound
Human Reproduction vol.12 no.5 pp. 905 909, 1997 Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound E.Carmina 1, L.Wong 2, L.Chang 2, R.J.Paulson 2, disturbance of the IGF/IGFBP-l
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea
More informationTestosterone decreases adiponectin levels in female to male transsexuals
DOI: 10.1111/j.1745-7262.2006.00204.x www.asiaandro.com. Clinical Experience. Testosterone decreases adiponectin levels in female to male transsexuals Marta Berra 1, Francesca Armillotta 1, Laura D Emidio
More informationAssociations among Lifestyle Status, Serum Adiponectin Level and Insulin Resistance
ORIGINAL ARTICLE Associations among Lifestyle Status, Serum Adiponectin Level and Insulin Resistance Hirokazu YOKOYAMA, Hiroshi HIROSE, Hideki OHGO* and Ikuo SAITO Abstract Objective The aim of this study
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome What is Polycystic Ovarian Syndrome? Polycystic Ovarian Syndrome (PCOS) is characterized by the presence of multiple ovarian cysts and excess androgen production. Clinical Features
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationInvestigation of adrenal functions in patients with idiopathic hyperandrogenemia
European Journal of Endocrinology (26) 155 37 311 ISSN 84-4643 CLINICAL STUDY Investigation of adrenal functions in patients with idiopathic hyperandrogenemia Hulusi Atmaca, Fatih Tanriverdi 1, Kursad
More informationPolycystic ovary syndrome (PCOS) Polycystic ovary syndrome: Why are women at increased risk of type 2 diabetes? Article.
Article Polycystic ovary syndrome: Why are women at increased risk of type 2 diabetes? Julie Tomlinson Citation: Tomlinson J (2016) Polycystic ovary syndrome: Why are women at increased risk of type 2
More informationDr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO
Dr Stella Milsom Endocrinologist Fertility Associates Auckland 12:30-12:40 When Puberty is PCO Puberty or Polycystic Ovary Syndrome? Stella Milsom Endocrinologist Auckland DHB, University of Auckland,
More informationPlasma adiponectin and insulin resistance in women with polycystic ovary syndrome
POLYCYSTIC OVARY SYNDROME Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome Mohammed Salleh M. Ardawi, Ph.D., F.R.C.Path., a and Abdulrahim A. Rouzi, F.R.C.S.C. b a Department
More informationCan Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?
www.ijpm.in www.ijpm.ir Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? Ferdous Mehrabian, Maryam Afghahi Department
More informationNitasha Garg 1 Harkiran Kaur Khaira. About the Author
https://doi.org/10.1007/s13224-017-1082-4 ORIGINAL ARTICLE A Comparative Study on Quantitative Assessment of Blood Flow and Vascularization in Polycystic Ovary Syndrome Patients and Normal Women Using
More informationEffect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 71, NO. 2, FEBRUARY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effect of troglitazone
More informationThe prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria
Prace oryginalne/original papers Endokrynologia Polska/Polish Journal of Endocrinology Tom/Volume 62; Numer/Number 3/2011 ISSN 0423 104X The prevalence of polycystic ovary syndrome in Iranian women based
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Study on Assessment of Testosterone, Insulin Resistance and HbA1c in Women with Polycystic
More informationPregnancy complications and glucose intolerance in women with polycystic ovary syndrome
Endocrine Journal 2015, 62 (11), 1017-1023 Original Pregnancy complications and glucose intolerance in women with polycystic ovary syndrome Mari Sawada, Hisashi Masuyama, Kei Hayata, Yasuhiko Kamada, Keiichiro
More information12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman
Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society
More informationComparative study of metabolic profile of women presenting with polycystic ovary syndrome in relation to body mass index
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Akshaya S et al. Int J Reprod Contracept Obstet Gynecol. 2016 Aug;5(8):2561-2565 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationINSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview
INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences PBL MBBS III VJ Temple 1 Insulin Resistance: What is
More informationOverview of Reproductive Endocrinology
Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,
More informationWhat every dermatologist should know about Polycystic Ovary Syndrome (PCOS)
What every dermatologist should know about Polycystic Ovary Syndrome (PCOS) Kanade Shinkai, MD PhD University of California, San Francisco Associate Professor of Dermatology I have no conflicts of interest
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Guideline for the Investigation and Management of Polycystic Ovary Syndrome Author: Contact Name and Job Title
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.14 Hyperinsulinemia in Polycystic Ovary Syndrome
More informationHyperandrogenism. Dr Jack Biko. MB. BCh (Wits), MMED O & G (Pret), FCOG (SA), Dip Advanced Endoscopic Surgery(Kiel, Germany)
Hyperandrogenism Dr Jack Biko MB. BCh (Wits), MMED O & G (Pret), FCOG (SA), Dip Advanced Endoscopic Surgery(Kiel, Germany) 2012 Hyperandrogenism Excessive production of androgens Adrenal glands main source
More informationS. AMH in PCOS Research Insights beyond a Diagnostic Marker
S. AMH in PCOS Research Insights beyond a Diagnostic Marker Dr. Anushree D. Patil, MD. DGO Scientist - D National Institute for Research in Reproductive Health (Indian Council of Medical Research) (Dr.
More informationDiagnosis and Management of Polycystic Ovary Syndrome During Adolescence: Questions and Controversies
Diagnosis and Management of Polycystic Ovary Syndrome During Adolescence: Questions and Controversies 2017 Illinois-AACE 2017 Annual Meeting October 14, 2017 Learning Objectives 1) Understand the challenges
More informationAssociation between adipose tissue expression and serum levels of leptin and adiponectin in women with polycystic ovary syndrome
Association between adipose tissue expression and serum levels of leptin and adiponectin in women with polycystic ovary syndrome S.B. Lecke 1,2, D.M. Morsch 1,2 and P.M. Spritzer 1,2 1 Unidade de Endocrinologia
More informationOutlook PCOS: a diagnostic challenge
RBMOnline - Vol 8. No 6. 2004 644-648 Reproductive BioMedicine Online; www.rbmonline.com/article/1274 on web 5 April 2004 Outlook PCOS: a diagnostic challenge Dr Ricardo Azziz Dr Azziz is currently Chairman
More informationClinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE
Clinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE Includes guidance for the distinction between adrenarche, precocious puberty and other
More informationClinical Profile Polycystic Ovarian Syndrome Cases
ORIGINAL RESEARCH www.ijcmr.com - 100 Cases Himabindu Sangabathula 1, Neelima Varaganti 1 ABSTRACT Introduction: Polycystic ovary syndrome (PCOS) is most common endocrine disorders of reproductive age
More informationSalivary Versus Serum Approaches in Assessment of Biochemical Hyperandrogenemia
Original Article Salivary Versus Serum Approaches in Assessment of Biochemical Hyperandrogenemia Mohamed Nabih El Gharib, Sahar Mohey El Din Hazaa 1 Departments of Obstetrics and Gynecology, and 1 Clinical
More informationThe Severity of Menstrual Dysfunction as a Predictor of Insulin Resistance in PCOS
JCEM ONLINE Brief Report Endocrine Research The Severity of Menstrual Dysfunction as a Predictor of Insulin Resistance in PCOS Meredith Brower, Kathleen Brennan, Marita Pall, and Ricardo Azziz Department
More informationCam type Femoroacetabular Impingement associated with Marker for Hyperandrogenism in Women
Cam type Femoroacetabular Impingement associated with Marker for Hyperandrogenism in Women Andrew B. Wolff, MD a Torie Plowden, MD b Alexandra Napoli, BA a Benjamin McArthur, MD a Erin F. Wolff, MD b a
More informationOriginal Investigation. 94 Endocrine Oncology and Metabolism. Jovanovska et al
Original Investigation Sensitivity and specificity of anti-mülerian hormone in the diagnosis of polycystic ovary syndrome in a macedonian population of women of reproductive age: a cross-sectional study
More informationAmenorrhoea: polycystic ovary syndrome
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationIMPACT OF NUTRITION ON GYNECOLOGICAL HEALTH OF FEMALE ADOLESCENTS
IMPACT OF NUTRITION ON GYNECOLOGICAL HEALTH OF FEMALE ADOLESCENTS Kedikova S. MD, PhD Medical University Sofia, Bulgaria University Hospital Maichin dom Sofia NUTRITION WHO - Nutrition is the intake of
More informationPolycystic Ovarian Syndrome (PCOS) LOGO
Polycystic Ovarian Syndrome (PCOS) Ma qianhong Ob/Gyn Department LOGO Contents Epidemiology and Definition Pathophysiology, Endocrinological Features Diagnostic Criteria Treatment Prognosis Introduction
More informationCase Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation
Polycystic Ovarian Syndrome: Treatment Goals and Options Marc Cornier, MD Division of Endocrinology, Metabolism and Diabetes Colorado Center for Health and Wellness University of Colorado School of Medicine
More informationDiagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome
Endocrine Journal 2007, 54 (2), 233 238 Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome TAKESHI IWASA, TOSHIYA MATSUZAKI, MASAHIRO MINAKUCHI, NAOKO
More informationResearch Article Does Polycystic Ovary Syndrome Itself Have Additional Effect on Apelin Levels?
Obstetrics and Gynecology International, Article ID 536896, 4 pages http://dx.doi.org/10.1155/2014/536896 Research Article Does Polycystic Ovary Syndrome Itself Have Additional Effect on Apelin Levels?
More informationPregnancy outcome in women with polycystic ovary syndrome
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Nivedhitha VS et al. Int J Reprod Contracept Obstet Gynecol. 2015 Aug;4(4):1169-1175 www.ijrcog.org pissn 2320-1770 eissn
More informationInsulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study
Human Reproduction, Vol.0, No.0 pp. 1 9, 2011 doi:10.1093/humrep/der418 Hum. Reprod. Advance Access published December 5, 2011 ORIGINAL ARTICLE Reproductive endocrinology Insulin resistance and endocrine
More informationRotterdam Criteria 9/30/2017. A Changing Paradigm in PCOS. Polycystic Ovary Syndrome - Is the Cardiometabolic Risk Increased After Menopause?
Disclosure Polycystic Ovary Syndrome - Is the Cardiometabolic Risk Increased After Menopause? Fractyl laboratories, Inc Anuja Dokras, MD., Ph.D. Professor of Obstetrics and Gynecology Director PENN PCOS
More informationWHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED
WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED Ricardo Azziz, M.D., M.P.H., M.B.A. Chief Officer of Academic Health & Hospital Affairs State University of New York (SUNY)
More informationPrevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai
Prevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai Principal Investigator Co- Investigators Consultant Collaborating Hospital Dr. Beena Joshi Dr. Srabani Mukherji
More informationComparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome
Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome William W. Hurd, M.D., M.Sc., M.P.H., a Mohamed Y. Abdel-Rahman, M.D., a,d Salah A. Ismail,
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationWEIGHT CHANGE AND ANDROGEN LEVELS DURING CONTRACEPTIVE TREATMENT OF WOMEN AFFECTED BY POLYCYSTIC OVARY
ENDOCRINE REGULATIONS, VOL. 40, 119-123, 2006 119 WEIGHT CHANGE AND ANDROGEN LEVELS DURING CONTRACEPTIVE TREATMENT OF WOMEN AFFECTED BY POLYCYSTIC OVARY J. VRBIKOVA, K. DVORAKOVA, M. HILL, L. STARKA Institute
More informationSCREENING OF POLYCYSTIC OVARIAN SYNDROME AMONG ADOLESCENT GIRLS AT CAIRO UNIVERSITY
SCREENING OF POLYCYSTIC OVARIAN SYNDROME AMONG ADOLESCENT GIRLS AT CAIRO UNIVERSITY Sahar Mansour Ibrahim, Yossria Ahmed Elsayed, Reda Esmail Reyad 4 and Hanan Fahmy Azzam 1* 2 3 1 Assistant Lecturer,
More informationPolycystic Ovary Disease: A Common Endocrine Disorder in Women
Polycystic Ovary Disease: A Common Endocrine Disorder in Women Paul Kaplan, M.D. Clinical Professor of Reproductive Endocrinology - OHSU Courtesy Senior Research Associate, Human Physiology University
More informationIN SUMMARY HST 071 NORMAL & ABNORMAL SEXUAL DIFFERENTIATION Fetal Sex Differentiation Postnatal Diagnosis and Management of Intersex Abnormalities
Harvard-MIT Division of Health Sciences and Technology HST.071: Human Reproductive Biology Course Director: Professor Henry Klapholz IN SUMMARY HST 071 Title: Fetal Sex Differentiation Postnatal Diagnosis
More informationROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME
ORIGINAL ARTICLE ROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME 1 2 3 Samdana Wahab, Farnaz, Rukhsana Karim ABSTRACT Objective: To assess the role of Metformin in Polycystic ovarian syndrome (PCOS).
More informationPolycystic Ovary Syndrome Therapy Dr. Pilar Vigil MD, PhD, FACOG
Polycystic Ovary Syndrome Therapy Dr. Pilar Vigil MD, PhD, FACOG What is an ovulatory dysfunction? Mrs. Susana Godoy, Nurse-Midwife San José, Costa Rica Abril 2018 PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE
More informationMetabolic syndrome in females with polycystic ovary syndrome and International Diabetes Federation criteria
doi:10.1111/j.1447-0756.2007.00685.x J. Obstet. Gynaecol. Res. Vol. 34, No. 1: 62 66, February 2008 Metabolic syndrome in females with polycystic ovary syndrome and International Diabetes Federation criteria
More informationPolycystic Ovary Syndrome (PCOS):
Polycystic Ovary Syndrome (PCOS): Current diagnosis and treatment Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the end of this presentation,
More informationClinical Study Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS
International Endocrinology Volume 2012, Article ID 434830, 5 pages doi:10.1155/2012/434830 Clinical Study Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS Kim Forrester-Dumont,
More information3. Metformin therapy for PCOS
1. Introduction The key clinical features of polycystic ovary syndrome (PCOS) are hyperandrogenism (hirsutism, acne, alopecia) and menstrual irregularity with associated anovulatory infertility. 1 The
More informationMetformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study
The Journal of Obstetrics and Gynecology of India (September-October 2012) 62(5):551 556 DOI 10.1007/s13224-012-0183-3 ORIGINAL ARTICLE Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative
More informationElevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance
Diabetologia (2007) 50:1033 1037 DOI 10.1007/s00125-007-0610-7 SHORT COMMUNICATION Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance
More informationThe contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome
Human Reproduction vol.14 no.2 pp.307 311, 1999 The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome E.Carmina 1, F.Gonzalez 2, A.Vidali
More informationCase. 24 year old female presented to your office complaining of excess hair growth on her face and abdomen. Questions?
Hirsutism Case 24 year old female presented to your office complaining of excess hair growth on her face and abdomen Questions? Started around puberty with gradual progression Irregular menstrual cycle
More informationDiabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome
Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome John E. Nestler, M.D. William Branch Porter Professor of Medicine Chair, Department of Internal Medicine Virginia Commonwealth University
More informationX/99/$03.00/0 Vol. 84, No. 5 The Journal of Clinical Endocrinology & Metabolism Copyright 1999 by The Endocrine Society
0021-972X/99/$03.00/0 Vol. 84, No. 5 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 1999 by The Endocrine Society A New Contributing Factor to Polycystic Ovary Syndrome:
More informationUniversity of Cape Town
P a g e 1 The Polycystic Ovary Syndrome a comparison of the presentation in adolescents compared to women aged 35 years and older attending the Gynaecological Endocrine clinic at Groote Schuur Hospital.
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationMini Review Excessive Androgen Exposure as An Etiological Factor of Polycystic Ovary Syndrome
J. Mamm. Ova Res. Vol. 31 (1), 23 30, 2014 23 Mini Review Excessive Androgen Exposure as An Etiological Factor of Polycystic Ovary Syndrome Tsuyoshi Baba 1*, Toshiaki Endo 1, Sayaka Adachi 1, Keiko Ikeda
More information2-Hypertrichosis:- Hypertrichosis is the
Hirsutism And Virilization Hirsutism:- Is the development of androgen-dependent dependent terminal body hair in a woman in places in which terminal hair is normally not found, terminal body hairs are the
More informationPolycystic ovarian syndrome: Are radiology departments contributing to the misdiagnosis?
Polycystic ovarian syndrome: Are radiology departments contributing to the misdiagnosis? Poster No.: C-1238 Congress: ECR 2010 Type: Scientific Exhibit Topic: Genitourinary Authors: G. Tony, N. V. Gurjar,
More informationSCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY
1 SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL SEMINAR: SEX HORMONES PART 1 An Overview What are steroid hormones? Steroid
More informationFLASH CARDS. Kalat s Book Chapter 11 Alphabetical
FLASH CARDS www.biologicalpsych.com Kalat s Book Chapter 11 Alphabetical alpha-fetoprotein alpha-fetoprotein Alpha-Fetal Protein (AFP) or alpha-1- fetoprotein. During a prenatal sensitive period, estradiol
More informationMetabolic changes in menopausal transition
Metabolic changes in menopausal transition Terhi T. Piltonen M.D., Associate Professor Consultant, Clinical Researcher for the Finnish Medical Foundation Department of Obstetrics and Gynecology PEDEGO
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More informationResearch Article. Ramanand SJ 1, Raparti GT 2 *, Halasawadekar NR 1, Ramanand JB 3, Kumbhar AV 1, Shah RD 1
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Ramanand SJ et al. Int J Reprod Contracept Obstet Gynecol. 2016 Sept;5(9):3181-3185 www.ijrcog.org pissn 2320-1770 eissn
More informationMETABOLIC SYNDROME IN REPRODUCTIVE FEMALES
METABOLIC SYNDROME IN REPRODUCTIVE FEMALES John J. Orris, D.O., M.B.A Division Head, Reproductive Endocrinology & Infertility, Main Line Health System Associate Professor, Drexel University College of
More informationJMSCR Vol 07 Issue 01 Page January 2019
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i1.55 Original Research Article A Study
More informationPolycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology
Polycystic Ovarian Syndrome Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology Outline Definition Symptoms Causal factors Diagnosis Complications Treatment Why are we talking about
More informationReproductive Medicine and Surgery Unit, University of Sheffield, Sheffield Teaching Hospitals, Jessop Wing, Tree Root Walk, Sheffield S10 2SF, UK 2
RBMOnline - Vol 19. No 4. 2009 572 576 Reproductive BioMedicine Online; www.rbmonline.com/article/4100 on web 19 August 2009 Article How common is polycystic ovary syndrome in recurrent miscarriage? Dr
More informationEstimation of serum 25 hydroxy vitamin D level and its correlation with metabolic and endocrine dysregulation in women with PCOS
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Solanki V et al. Int J Reprod Contracept Obstet Gynecol. 2017 Jul;6(7):3085-3090 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20172939
More informationCARDIOVASCULAR RISK FACTORS. Harpal S Randeva. Warwick Medical School University of Warwick, UK
NORDIC FEDERATION OF SOCIETIES OF OBSTETRICS AND GYNAECOLOGY November, 2010 POLYCYSTIC OVARY SYNDROME THROUGH LIFE CARDIOVASCULAR RISK FACTORS Harpal S Randeva Warwick Medical School University of Warwick,
More informationCORRELATION OF OBESITY, INSULIN RESISTANCE AND LIPID PROFILE IN WOMEN WITH PCOS IN KIMS HOSPITAL BANGALORE Shashikala H. Gowda 1, Mansi Dhingra 2
CORRELATION OF OBESITY, INSULIN RESISTANCE AND LIPID PROFILE IN WOMEN WITH PCOS IN KIMS HOSPITAL BANGALORE Shashikala H. Gowda 1, Mansi Dhingra 2 HOW TO CITE THIS ARTICLE: Shashikala H. Gowda, Mansi Dhingra.
More informationThe menstrual cycle. François Pralong
The menstrual cycle François Pralong Services d Endocrinologie, Diabétologie et Métabolisme, Hôpitaux Universitaires de Genève et Lausanne Centre des Maladies CardioVasculaires et Métaboliques, Lausanne
More informationEditorial 2. Polycystic Ovary Syndrome: From in utero to Menopause INTRODUCTION GENETICS OF PCOS IN UTERO FETAL PROGRAMMING
Editorial 2 Polycystic Ovary Syndrome: From in utero to Menopause INTRODUCTION The syndrome of polycystic ovaries is typically diagnosed during the adolescent period or during the reproductive years, when
More informationDoes free androgen index predict subsequent pregnancy outcome in women with recurrent miscarriage?
Human Reproduction Vol.23, No.4 pp. 797 802, 2008 Advance Access publication on February 8, 2008 doi:10.1093/humrep/den022 Does free androgen index predict subsequent pregnancy outcome in women with recurrent
More informationDiagnostic features of polycystic ovary syndrome
REVIEW article Diagnostic features of polycystic ovary syndrome 3 N Barday-Karbanee, MB ChB, DTM&H, BSc Hons (Reprod Biol) Berg Medicross, Newville, Johannesburg T I Siebert, MMed (O&G), FCOG M H Botha,
More informationPrevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study
Prevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study Mousa Mohsen Ali* Wasan Ghazi* HayderAamerAbboud^ *Kerbala University, College of Medicine, Gynecology
More informationUfuk University, Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey; 2
RBMOnline - Vol 19. No 5. 2009 721 726 Reproductive BioMedicine Online; www.rbmonline.com/article/4092 on web 24 August 2009 Article Obesity and insulin resistance associated with lower plasma vitamin
More informationThe prevalence of polycystic ovaries in healthy women
Acta Obstet Gynecol Scand 1999; 78: 137 141 Copyright C Acta Obstet Gynecol Scand 1999 Printed in Denmark all rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More informationAbnormal glucose tolerance in Chinese women with polycystic ovary syndrome
Human Reproduction Vol.21, No.8 pp. 2027 2032, 2006 Advance Access publication May 9, 2006. doi:10.1093/humrep/del142 Abnormal glucose in Chinese women with polycystic ovary syndrome Xiaoli Chen, Dongzi
More informationObjectives 1. Be able to describe the classic presentation and diagnostic criteria 2. Be able to explain long-term health concerns associated with the diagnosis 3. Understand what basic treatment options
More informationGonadotrophin treatment in patients with Polycystic Ovary Syndrome
Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218
More informationFemale androgen profiles by MS for PCOS patients. CS Ho APCCMS 2010, Hong Kong 14 January 2010
Female androgen profiles by MS for PCOS patients CS Ho APCCMS 2010, Hong Kong 14 January 2010 873 women with increased serum androgens Androgen-secreting neoplasms 0.2% Classical CAH 0.6% Non-classical
More information